A Study of ADRX-0706 in Select Advanced Solid Tumors - Trial NCT06036121
Access comprehensive clinical trial information for NCT06036121 through Pure Global AI's free database. This Phase 1 trial is sponsored by Adcentrx Therapeutics and is currently Recruiting. The study focuses on Solid Tumors. Target enrollment is 114 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Adcentrx Therapeutics
Timeline & Enrollment
Phase 1
Sep 26, 2023
Dec 01, 2026
Primary Outcome
Incidence of adverse events
Summary
The primary purpose of this study is to assess the safety, tolerability, and
 pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select
 advanced solid tumors.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06036121
Non-Device Trial